Introduction {#Sec1}
============

Diabetes is a major social burden, whose prevalence has more than doubled in the last decades \[[@CR1]\]. In 2013, the International Diabetes Federation estimated that more than 382 million people are currently affected by diabetes, and forecast that this number will almost double by 2035 \[[@CR2]\].

Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are pre-diabetic states characterized by elevated glycaemia and associated with insulin resistance and increased cardiovascular risk \[[@CR3]\].

The Look AHEAD Trial proved intensive lifestyle intervention to be quite effective in reducing the impact of cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM) \[[@CR4]\], and some studies and meta-analyses showed how physical activity and dietary interventions can lead to a decrease in fasting plasma glucose level (FPG) and prevent or slow down the transition between IFG, IGT and T2DM \[[@CR3], [@CR5]\].

Moreover, more than 40 nutraceutical substances have been studied in order to improve lipid and glucose metabolism, and some clinical trials demonstrated a cholesterol-lowering activity, an improvement of glucose metabolism and inflammatory parameters, besides a possible positive influence on cardiovascular prognosis \[[@CR6]\].

*Berberis aristata* (tree turmeric) is a shrub containing the quaternary ammonium salt berberine. Berberine has been demonstrated to improve glucose and lipid metabolism disorders, and to reduce atherogenes is and endothelial inflammation in diabetic patients, with clinical effects similar to those of metformin \[[@CR7], [@CR8]\]. Its effect on glucose metabolism, in fact, like metformin, does not depend on insulin concentration \[[@CR9]\].

*Lagerstroemia speciosa*, also known as banaba, is a tropical plant found in the Southeast area of Asia. It has been shown to have, among others, hypoglycaemic and antihyperlipidemic effects, due to corosolic acid and ellagitannins, two of its components \[[@CR10]\]. The action mechanisms involved consist of enhanced cellular uptake of glucose, impaired hydrolysis of sucrose and starches, decreased gluconeogenesis and the regulation of lipid metabolism. A supplementation with banaba has proved to be safe and well tolerated in clinical trials \[[@CR11]\]. In addition, its action on both glucose and lipid metabolism could be useful in the management of metabolic syndrome \[[@CR12]\].

*Curcuma longa* (turmeric) has long been used in Oriental traditional medicine because of its anti-inflammatory properties. Its main component, curcumin, is responsible foranti-inflammatory, anti-neoplastic, antioxidant and antimicrobial effects \[[@CR13]\], with direct therapeutic properties in diabetic subjects \[[@CR14]\].

Alpha lipoic acid has an antioxidant effect, with a provenanti-inflammatory and insulin like activity, suggesting a therapeutic role in the management of diabetic and pre diabetic subjects \[[@CR15]\].

Chromium picolinate has also proved to be a hypoglycaemic and insulin-resistance reducing substance in patients with T2DM \[[@CR16]\].

Folic acid, part of the group B vitamins, has an antioxidant activity. Its supplementation in T2DM patients, together with B~12~ vitamins, has a positive effect on insulin resistance, fasting plasma glucose level and homocysteinaemia \[[@CR17]\].

The association of several nutraceuticals, in particular in patients with two or more risk factors for cardiovascular diseases, has been proved to have a synergistic effect \[[@CR18], [@CR19]\].

The aim of this trial is thus to test the effectiveness and safety of a combination of *Lagerstroemia speciosa, Berberis aristata, Curcuma longa,* Alpha-lipoic acid, Chrome picolinate and Folic acid in subjects with impaired fasting glucose, assessing its short-term effect on glucose and lipid metabolism.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This double-blind, parallel group, placebo-controlled, randomized clinical trial was carried out in 40 adult subjects affected by impaired fasting glucose (FPG = 100--125 mg/dL) in primary prevention of cardiovascular disease, consecutively enrolled in the outpatient service of cardiovascular disease prevention in the Medical and Surgical Sciences Department of the University of Bologna.

The study consisted of a trial with a total duration of 10 weeks. During the first 2 weeks, patients received standard behavioural and qualitative (not quantitative) dietary suggestions to correct unhealthy habits. In particular, subjects were instructed to follow a general indication of a Mediterranean diet, avoiding excessive intake of dairy products and red meat derived products during the study, and maintaining overall constant dietary habits. Individuals were also generically encouraged to increase their physical activity by walking briskly for 20--30 min, 3--5 times per week, or by cycling. After a period of 2 weeks of dietary habits correction only, patients continued the diet and began a period of 8 weeks of treatment with nutraceutical or placebo. Data related to lipid pattern, insulin resistance, liver function and hsCRP were obtained at the baseline and at the end of the study.

The only inclusion criteria was the repeated measure of fasting plasma glucose between 100 and 125 mg/dL.

Exclusion criteria were:Diagnosis of T2DM or assumption of hypoglycaemic drugs/supplementObesity (BMI \>30 kg/m^2^)Secondary prevention for cardiovascular diseaseEndocrinological conditions in a failure state (e.g. hypothyroidism, Cushing Syndrome, PCOS)Occasional, programmed or chronic assumption of corticosteroids.

The study was fully conducted in accordance with the Declaration of Helsinki, its protocol was approved by the Ethical Committee of the University of Bologna, and informed consent was obtained from all patients before their inclusion in the study.

Treatments {#Sec4}
----------

After 2 weeks of diet and physical activity stabilization, patients were allocated to treatment with an indistinguishable pill including either placebo or active product containing *Lagerstroemia speciosa* extract (1% corosolic acid) 250 mg, *Berberis aristata* extract (98% berberine) 155 mg, curcuma extract 125 mg, chromium picolinate 1.3 mg, folic acid 0.15 mg, solvent-free alpha lipoic acid 110 mg (kindly provided by Pegaso Srl, Arbizzano di Negrar, VR, Italy), two pills per day.

Clinical and laboratory data were obtained at the baseline and after the end of the treatment period.

Randomization was done by assigning an alphabetical code to each batch code (corresponding to treatment or placebo) impressed on the pillbox. Codes were then kept in a sealed envelope, which was not opened until the end of the trial. Pillboxes were then mixed, and the investigators assigned a blinded pillbox to each enrolled patient.

Throughout the study, we instructed patients to take the first dose on the day after they were given the study product. At the same time, all unused products were returned to the investigator.

Assessments {#Sec5}
-----------

Personal data, CVD history and pharmaceutical anamnesis of each patient were collected at the beginning of the trial. Anthropometrical parameters, such as body weight, waist circumference (WC) and Body Mass Index (BMI) were collected both at the beginning and during the trial, together with haemodynamic and biochemical parameters. BMI was calculated as weight in kilograms divided by the square of height in metres. Haemodynamic parameters were collected measuring orthostatic and clinostatic systolic and diastolic blood pressure (mean value of three interval measures). Also orthostatic and clinostatic wrist blood pressure (mean value of three interval measures) and cardiac frequency were collected.

All biochemical parameters were obtained after a 12-h overnight fast and The following parameters were obtained or calculated through appropriate formulae: total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), TG, LDL-C, non-HDL cholesterol (non HDL-C), fasting plasma glucose (FPG), fasting insulin, Serum Uric Acid (SUA), and hsCRP \[[@CR20]\]. All measurements were centrally performed in the laboratory of our department with standardized methods by trained biologists \[[@CR21]\].

HOMA-IR is the simplest and most commonly used method to estimate insulin resistance. It was calculated as the product of basal glucose (mmol/L) and fasting insulin (μU/mL) divided by 22.5 \[[@CR22]\].

Adherence to behavioural counselling and to treatment/placebo, tolerability, acceptability and compliance were also assessed.

Statistical Analyses {#Sec6}
--------------------

Data were analysed using intention to treat by means of the Statistical Package for Social Science (SPSS) 21.0, version for Windows. Normally distributed baseline characteristics of the population were compared using Student's *t* test, non-normally distributed parameters using Mann--Whitney *U* test. Two-way analyses of variance for crossover design were used to assess the effect of treatment during the assumption of placebo or treatment. All data are expressed as means and standard deviation (SD). To verify the basic assumptions of crossover design, besides the evaluation of period effect, the presence of a carryover effect was excluded. Level of statistical significance was set on *p* = 0.05.

Results {#Sec7}
=======

The main characteristics of the enrolled patients are summed up in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of the patients enrolled by treatment groupActive (N. 20; M: 9, F: 11)Placebo (N. 20; M: 8, F: 12)MeanSDMeanSDAge (years)54.611.351.912.5Waist circumference (cm)99.99.498.18.9Body Mass Index (kg/m^2^)27.01.627.21.9Systolic blood pressure (mmHg)132.711.2128.512.8Diastolic blood pressure (mmHg)80.46.379.77.0Total cholesterol (mg/dL)220.916.7225.813.0Triglycerides (mg/dL)186.445.7171.853.5HDL-cholesterol (mg/dL)46.75.149.14.4LDL-cholesterol (mg/dL)156.817.3154.311.1Non-HDL cholesterol (mg/dL)174.919.3187.121.4Fasting plasma glucose (mg/dL)111.63.6115.73.9Fasting insulinaemia (mcL/mL)19.44.118.83.3HOMA Index5.210.845.440.73hsC-reactive protein (mg/L)2.980.242.920.23

At the baseline, the two treatment sequence groups were balanced for all the investigated parameters. All the patients completed the study and no one experienced adverse events during the trial.

Compared to baseline values, no change was observed after both treatments as regards WC, BMI, systolic and diastolic blood pressure, total and LDL-cholesterol, and hsCRP (Table [2](#Tab2){ref-type="table"}).Table 2Pre- and post-treatment valuesActive T0 (pre-treatment)Active T1 (post-treatment)Placebo T0 (pretreatment)Placebo T1 (post-treatment)MeanSDMeanSDMeanSDMeanSDWaist circumference (cm)99.99.497.18.697.18.997.99.3Body Mass Index (kg/m^2^)27.01.626.82.127.21.927.01.8Systolic blood pressure (mmHg)132.711.2130.510.8128.512.8127.910.4Diastolic blood pressure (mmHg)80.46.379.66.079.77.079.56.9Total cholesterol (mg/dL)220.916.7225.823.0225.813.0220.313.8**Triglycerides** (mg/dL)186.445.7121.8\*^,^°53.5171.853.5149.9\*49.6**HDL-C (mg/dL)**46.75.153.1\*^,^°5.449.14.450.44.3LDL-C (mg/dL)156.817.3148.316.1154.311.1135.518.5Non-HDL-C (mg/dL)174.919.3158.1\*16.4187.121.4169.9\*17.3Fasting glucose (mg/dL)110.63.694.6\*3.9114.73.9109.9\*4.7**Insulinaemia** (mcL/mL)19.44.116.8\*^,^°2.318.83.318.12.4**HOMA Index**5.200.843.92\*^,^°1.135.440.734.931.17hsCRP (mg/L)2.980.242.790.282.920.232.770.27\* *p* \< 0.05 vs. baseline; ° *p* \< 0.05 vs. placebo

Non HDL-cholesterol and fasting plasma glucose similarly improved in both treated groups (*p* \< 0.05).

Triglycerides were reduced in both groups (*p* \< 0.05), but more in the nutraceutical treated one than in the control group (*p* \< 0.05).

HDL-cholesterol, Fasting insulinaemia and HOMA-index improved in the nutraceutical treated group, only (*p* \< 0.05), when compared both to baseline and to the control group (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}).Table 3Row effect of the active treatment and of the placebo on glico-metabolic parametersDelta after treatment groupDelta after placebo group**Triglycerides** (mg/dL)65.6\*^,^°9.721.3\*3.8**HDL-C (mg/dL)**7.4\*^,^°1.11.10.4LDL-C (mg/dL)9.95.318.18.4Non-HDL-C (mg/dL)16.8\*3.318.0\*4.4Fasting glucose (mg/dL)17.2\*3.67.7\*2.9**Insulinaemia** (mcL/mL)2.8\*^,^°1.10.80.7**HOMA Index**1.28\*^,^°0.330.520.31\* *p* \< 0.05 vs. baseline; ° *p* \< 0.05 vs. placebo

Discussion {#Sec8}
==========

In our trial carried out on subjects with impaired fasting glucose, we observed that a nutraceutical mixture was able to improve on the short term the serum level of TG (−34.7%), HDL-C (+13.7%), FPI (−13.4%), and HOMA-Index (−25%) versus the baseline values (Fig. [1](#Fig1){ref-type="fig"}). All these parameters are related to insulin-resistance and metabolic syndrome. Considering that metabolic syndrome is a highly prevalent and incident condition \[[@CR23]\] associated with an increased risk of developing type 2 diabetes and cardiovascular disease \[[@CR24], [@CR25]\], the improvement of parameters related to the use of the tested product made it a possible interesting therapeutic tool, when associated with a balanced diet. Moreover, the observed results were at least partly expected, because the components of the tested mixture are all supported by an acceptable level of clinical evidence of efficacy \[[@CR26]\]. In particular, chlorogenic acid \[[@CR27]\], berberine \[[@CR28]\], curcumin \[[@CR29]\] and chromium picolinate \[[@CR30]\] have clearly demonstrated that they exert an insulin-sensitizing effect in humans. On the other hand, the lack of efficacy of the combined nutraceutical on the systemic inflammation evaluated by the measurement of the serum hsCRP is slightly in contrast with what was previously observed with berberine \[[@CR28]\] and curcumin \[[@CR29]\]: this is probably related to the low doses used of the single nutraceutical components and to the short duration of the treatment. Blood pressure also did non improved beyond the observed improvement of insulin-resistance related parameter, however this could be related to the short duration of the trial and the small improvement on HOMA-index observed.Fig. 1Effect of the tested combined nutraceutical on fasting plasma glucose and HOMA index (\**p* \< 0.05 vs. baseline)

Then, the tested product was associated with a high tolerability profile that is important to guarantee long-term compliance of the treatment.

Of course, our trial also has some important limitations. First of all the sample size was relatively small, but sufficient to detect the mean FPG difference supposed for the sample size calculation. Then the study was short: its duration was adequate to test the short-term effect, but we are not able to infer our results on the middle-long term. Finally, we did not evaluate an eventual rebound effect on stopping the treatment.

In conclusion, the tested combined nutraceutical was able to improve mildly but significantly several parameters related to insulin-resistance in subjects affected by impaired fasting glucose, both when compared to the baseline and to the control group. Further studies are needed to confirm the effectiveness of this approach to manage insulin-resistant patients on the long term.

The tested product and the related placebo were kindly furnished by Pegaso Srl, Arbizzano di Negrar, VR, Italy.
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